1. Home
  2. Analysis
  3. Kefzol
  4. Temaz

Kefzol and Temaz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kefzol and Temaz. Common interactions include pain among females and actinomycosis among males.

The phase IV clinical study analyzes what interactions people who take Kefzol and Temaz have. It is created by eHealthMe based on reports of 18 people who take Kefzol and Temaz from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

18 people who take Kefzol and Temaz together, and have interactions are studied.

What is Kefzol?

Kefzol has active ingredients of cefazolin sodium. eHealthMe is studying from 605 Kefzol users for its effectiveness, alternative drugs and more.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 38,819 Temaz users for its effectiveness, alternative drugs and more.

Number of Kefzol and Temaz reports submitted per year:

Kefzol and Temaz drug interactions.

Common Kefzol and Temaz drug interactions by gender *:

female:

  1. Pain
  2. Pulmonary embolism
  3. Renal failure chronic
  4. Encephalopathy

male:

  1. Actinomycosis
  2. Amyloidosis
  3. Ear pain
  4. Exposed bone in jaw
  5. Hepatitis c
  6. Herpes simplex
  7. Hypersensitivity
  8. Hypertension
  9. Hypothyroidism
  10. Infection

Common Kefzol and Temaz drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Pulmonary embolism

50-59:

  1. Pain
  2. Acute myocardial infarction
  3. Cardiac failure
  4. Cardiac failure congestive
  5. Cardiovascular disorder
  6. Myocardial infarction

60+:

  1. Encephalopathy
  2. Renal failure chronic
  3. Haematoma
  4. Joint effusion

Common conditions people have *:

  1. Breast Cancer: 2 people, 11.11%
  2. Type 2 Diabetes: 1 person, 5.56%
  3. Sedation: 1 person, 5.56%
  4. Menstrual Disorder (disease of menstrual cycle): 1 person, 5.56%
  5. High Blood Pressure: 1 person, 5.56%
  6. Birth Control: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Kefzol and Temaz?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Kefzol and Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Kefzol side effects:

Browse all side effects of Kefzol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Temaz side effects:

Browse all side effects of Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Kefzol interactions:

Browse all interactions between Kefzol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Temaz interactions:

Browse all interactions between Temaz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cefazolin sodium and temazepam (the active ingredients of Kefzol and Temaz, respectively), and Kefzol and Temaz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Kefzol and Temaz.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.